Foresee Pharmaceuticals announced that its consolidated revenue for April reached approximately NT$58.83 million, representing a 107% increase compared to the previous month and an 18% increase year-over-year. Cumulative consolidated revenue from January through April totaled approximately NT$169 million, marking a 10% year-over-year growth. Sales of CAMCEVI’s six-month formulation in the U.S. terminal market reached 2,219 units in April, a 36% increase from 1,630 units in March, setting a new record for this year.

The company noted that CAMCEVI’s six-month formulation was recently launched in Germany. Coordination with its licensing partner responsible for the EU market is still underway to establish a structured communication mechanism regarding sales data, and related royalty income will be recognized once confirmed. April’s consolidated revenue includes NT$40.32 million from product sales of the six-month formulation to U.S. distributors, NT$10.7 million from profit-sharing based on U.S. terminal market sales, and NT$7.81 million from service income.

CAMCEVI’s three-month formulation is currently undergoing substantive review for regulatory approval in both the U.S. and Europe. Foresee anticipates that related revenue will experience significant growth in the second half of the year, particularly with the expected milestone payment upon U.S. approval of the three-month formulation.

Resource: 逸達4月營收月增逾倍，CAMCEVI六個月劑型美國銷量創今年新高